A matching-adjusted indirect comparison of ELEVATE-TN versus SEQUOIA: acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive chronic lymphocytic leukemia

被引：0
|
作者：
Kittai, Adam
Allan, John
James, Dan
Bridge, Helen
Miranda, Miguel
Yong, Alan
Fam, Fady
Roos, Jack
Shetty, Vikram
Skarbnik, Alan
Davids, Matthew
机构：
来源：
LEUKEMIA & LYMPHOMA | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1550098
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [1] A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
    Allan, John N.
    Kittai, Adam S.
    James, Dan
    Ridge, Helen
    Miranda, Miguel
    Yong, Alan
    Fam, Fady
    Roos, Jack
    Shetty, Vikram
    Davids, Matthew S.
    Skarbnik, Alan
    BLOOD, 2023, 142
  • [2] Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naive Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Emeribe, Ugochinyere
    Gaitonde, Priyanka
    Cai, Ling
    BLOOD, 2021, 138
  • [3] Acalabrutinib ± obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: Elevate-TN four-year follow up.
    Sharman, Jeff Porter
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Pagel, John M.
    Kamdar, Manali K.
    Munir, Talha
    Corbett, Gillian
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Coutre, Steve E.
    Walker, Patricia
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Wierda, William G.
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Matching-adjusted indirect comparisons of efficacy and safety of Acalabrutinib versus Ibrutinib in treatment-naive chronic lymphocytic leukemia
    Dietrich, S.
    Davids, M.
    Telford, C.
    Abhyankar, S.
    Waweru, C.
    Ringshausen, I.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 72 - 72
  • [5] PATIENT-REPORTED OUTCOMES FROM THE PHASE 3, RANDOMIZED STUDY OF ACALABRUTINIB WITH OR WITHOUT OBINUTUZUMAB VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB FOR TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA (ELEVATE-TN)
    Walker, P.
    Sharman, J. P.
    Jurczak, W.
    Munir, T.
    Banerji, V
    Coutre, S.
    Woyach, J.
    Salles, G.
    Wierda, W. G.
    Patel, P.
    Wang, M. H.
    Emeribe, U.
    Flood, E.
    Byrd, J. C.
    Ghia, P.
    VALUE IN HEALTH, 2021, 24 : S3 - S4
  • [6] Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
    Munir, Talha
    Mohseninejad, Leyla
    Xu, Sheng
    Jevdjevic, Milica
    Bouwmeester, Walter
    Yang, Keri
    BLOOD, 2023, 142
  • [7] Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia
    Sharman, Jeff P.
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Pagel, John M.
    Flinn, Ian W.
    Kamdar, Manali
    Munir, Talha
    Walewska, Renata
    Corbett, Gillian
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Coutre, Steven
    Follows, George
    Walker, Patricia
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Cymbalista, Florence
    Woyach, Jennifer A.
    Ferrant, Emmanuelle
    Wierda, William G.
    Munugalavadla, Veerendra
    Yu, Ting
    Wang, Min Hui
    Byrd, John C.
    LEUKEMIA, 2022, 36 (04) : 1171 - 1175
  • [8] Acalabrutinib ± Obinutuzumab Vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
    Sharman, Jeff P.
    Egyed, Miklos
    Jurczak, Wojciech
    Skarbnik, Alan
    Patel, Krish
    Flinn, Ian W.
    Kamdar, Manali
    Munir, Talha
    Walewska, Renata
    Hughes, Marie
    Fogliatto, Laura Maria
    Herishanu, Yair
    Banerji, Versha
    Follows, George
    Walker, Patricia A.
    Karlsson, Karin
    Ghia, Paolo
    Janssens, Ann
    Cymbalista, Florence
    Byrd, John C.
    Ferrant, Emmanuelle
    Ferrajoli, Alessandra
    Wierda, William G.
    Munugalavadla, Veerendra
    Wachira, Catherine Wangui
    Wun, Chuan-Chuan
    Woyach, Jennifer A.
    BLOOD, 2023, 142
  • [9] Acalabrutinib ± obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up
    Martens, U. M.
    Sharman, J. P.
    Egyed, M.
    Jurczak, W.
    Skarbnik, A.
    Pagel, J. M.
    Kamdar, M.
    Munir, T.
    Corbett, G.
    Fogliatto, L. M.
    Herishanu, Y.
    Banerji, V
    Coutre, S.
    Walker, P.
    Karlsson, K.
    Ghia, P.
    Janssens, A.
    Wierda, W. G.
    Patel, P.
    Wang, M. H.
    Byrd, J. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 106 - 106
  • [10] Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia
    Davids, Matthew S.
    Telford, Claire
    Abhyankar, Sarang
    Waweru, Catherine
    Ringshausen, Ingo
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2342 - 2351
12345